Association between Serum Cystatin C and Diabetic Foot Ulceration in Patients with Type 2 Diabetes

A Cross-Sectional Study

Jie Zhao, Wuquan Deng, Yuping Zhang, Yanling Zheng, Lina Zhou, Johnson Boey, David G Armstrong, Gangyi Yang, Ziwen Liang, Bing Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Serum cystatin C (CysC) has been identified as a possible potential biomarker in a variety of diabetic complications, including diabetic peripheral neuropathy and peripheral artery disease. We aimed to examine the association between CysC and diabetic foot ulceration (DFU) in patients with type 2 diabetes (T2D). 411 patients with T2D were enrolled in this cross-sectional study at a university hospital. Clinical manifestations and biochemical parameters were compared between DFU group and non-DFU group. The association between serum CysC and DFU was explored by binary logistic regression analysis. The cut point of CysC for DFU was also evaluated by receiver operating characteristic (ROC) curve. The prevalence of coronary artery disease, diabetic nephropathy (DN), and DFU dramatically increased with CysC (P < 0.01) in CysC quartiles. Multivariate logistic regression analysis indicated that the significant risk factors for DFU were serum CysC, coronary artery disease, hypertension, insulin use, the differences between supine and sitting TcPO2, and hypertension. ROC curve analysis revealed that the cut point of CysC for DFU was 0.735 mg/L. Serum CysC levels correlated with DFU and severity of tissue loss. Our study results indicated that serum CysC was associated with a high prevalence of DFU in Chinese T2D subjects.

Original languageEnglish (US)
Article number8029340
JournalJournal of Diabetes Research
Volume2016
DOIs
StatePublished - 2016

Fingerprint

Cystatin C
Diabetic Foot
Type 2 Diabetes Mellitus
Cross-Sectional Studies
Serum
ROC Curve
Coronary Artery Disease
Logistic Models
Regression Analysis
Hypertension
Diabetic Neuropathies
Peripheral Arterial Disease
Diabetic Nephropathies
Peripheral Nervous System Diseases
Diabetes Complications
Foot
Biomarkers
Insulin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Association between Serum Cystatin C and Diabetic Foot Ulceration in Patients with Type 2 Diabetes : A Cross-Sectional Study. / Zhao, Jie; Deng, Wuquan; Zhang, Yuping; Zheng, Yanling; Zhou, Lina; Boey, Johnson; Armstrong, David G; Yang, Gangyi; Liang, Ziwen; Chen, Bing.

In: Journal of Diabetes Research, Vol. 2016, 8029340, 2016.

Research output: Contribution to journalArticle

Zhao, Jie ; Deng, Wuquan ; Zhang, Yuping ; Zheng, Yanling ; Zhou, Lina ; Boey, Johnson ; Armstrong, David G ; Yang, Gangyi ; Liang, Ziwen ; Chen, Bing. / Association between Serum Cystatin C and Diabetic Foot Ulceration in Patients with Type 2 Diabetes : A Cross-Sectional Study. In: Journal of Diabetes Research. 2016 ; Vol. 2016.
@article{e2ca866654e44b3aaecf6f38b507ab53,
title = "Association between Serum Cystatin C and Diabetic Foot Ulceration in Patients with Type 2 Diabetes: A Cross-Sectional Study",
abstract = "Serum cystatin C (CysC) has been identified as a possible potential biomarker in a variety of diabetic complications, including diabetic peripheral neuropathy and peripheral artery disease. We aimed to examine the association between CysC and diabetic foot ulceration (DFU) in patients with type 2 diabetes (T2D). 411 patients with T2D were enrolled in this cross-sectional study at a university hospital. Clinical manifestations and biochemical parameters were compared between DFU group and non-DFU group. The association between serum CysC and DFU was explored by binary logistic regression analysis. The cut point of CysC for DFU was also evaluated by receiver operating characteristic (ROC) curve. The prevalence of coronary artery disease, diabetic nephropathy (DN), and DFU dramatically increased with CysC (P < 0.01) in CysC quartiles. Multivariate logistic regression analysis indicated that the significant risk factors for DFU were serum CysC, coronary artery disease, hypertension, insulin use, the differences between supine and sitting TcPO2, and hypertension. ROC curve analysis revealed that the cut point of CysC for DFU was 0.735 mg/L. Serum CysC levels correlated with DFU and severity of tissue loss. Our study results indicated that serum CysC was associated with a high prevalence of DFU in Chinese T2D subjects.",
author = "Jie Zhao and Wuquan Deng and Yuping Zhang and Yanling Zheng and Lina Zhou and Johnson Boey and Armstrong, {David G} and Gangyi Yang and Ziwen Liang and Bing Chen",
year = "2016",
doi = "10.1155/2016/8029340",
language = "English (US)",
volume = "2016",
journal = "Journal of Diabetes Research",
issn = "2314-6745",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Association between Serum Cystatin C and Diabetic Foot Ulceration in Patients with Type 2 Diabetes

T2 - A Cross-Sectional Study

AU - Zhao, Jie

AU - Deng, Wuquan

AU - Zhang, Yuping

AU - Zheng, Yanling

AU - Zhou, Lina

AU - Boey, Johnson

AU - Armstrong, David G

AU - Yang, Gangyi

AU - Liang, Ziwen

AU - Chen, Bing

PY - 2016

Y1 - 2016

N2 - Serum cystatin C (CysC) has been identified as a possible potential biomarker in a variety of diabetic complications, including diabetic peripheral neuropathy and peripheral artery disease. We aimed to examine the association between CysC and diabetic foot ulceration (DFU) in patients with type 2 diabetes (T2D). 411 patients with T2D were enrolled in this cross-sectional study at a university hospital. Clinical manifestations and biochemical parameters were compared between DFU group and non-DFU group. The association between serum CysC and DFU was explored by binary logistic regression analysis. The cut point of CysC for DFU was also evaluated by receiver operating characteristic (ROC) curve. The prevalence of coronary artery disease, diabetic nephropathy (DN), and DFU dramatically increased with CysC (P < 0.01) in CysC quartiles. Multivariate logistic regression analysis indicated that the significant risk factors for DFU were serum CysC, coronary artery disease, hypertension, insulin use, the differences between supine and sitting TcPO2, and hypertension. ROC curve analysis revealed that the cut point of CysC for DFU was 0.735 mg/L. Serum CysC levels correlated with DFU and severity of tissue loss. Our study results indicated that serum CysC was associated with a high prevalence of DFU in Chinese T2D subjects.

AB - Serum cystatin C (CysC) has been identified as a possible potential biomarker in a variety of diabetic complications, including diabetic peripheral neuropathy and peripheral artery disease. We aimed to examine the association between CysC and diabetic foot ulceration (DFU) in patients with type 2 diabetes (T2D). 411 patients with T2D were enrolled in this cross-sectional study at a university hospital. Clinical manifestations and biochemical parameters were compared between DFU group and non-DFU group. The association between serum CysC and DFU was explored by binary logistic regression analysis. The cut point of CysC for DFU was also evaluated by receiver operating characteristic (ROC) curve. The prevalence of coronary artery disease, diabetic nephropathy (DN), and DFU dramatically increased with CysC (P < 0.01) in CysC quartiles. Multivariate logistic regression analysis indicated that the significant risk factors for DFU were serum CysC, coronary artery disease, hypertension, insulin use, the differences between supine and sitting TcPO2, and hypertension. ROC curve analysis revealed that the cut point of CysC for DFU was 0.735 mg/L. Serum CysC levels correlated with DFU and severity of tissue loss. Our study results indicated that serum CysC was associated with a high prevalence of DFU in Chinese T2D subjects.

UR - http://www.scopus.com/inward/record.url?scp=84988711921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988711921&partnerID=8YFLogxK

U2 - 10.1155/2016/8029340

DO - 10.1155/2016/8029340

M3 - Article

VL - 2016

JO - Journal of Diabetes Research

JF - Journal of Diabetes Research

SN - 2314-6745

M1 - 8029340

ER -